Clinical trial NCT00793676: Asthma, Inflammation and G Protein-coupled Receptors (GPCR)
Official title: G Protein Coupled Receptor (GPCR)Signature as Biomarker of Chronic Pulmonary Inflammatory Diseases and of Therapeutic Follow-up
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Asthma
COPD
Keywords: GPCR expression
transcriptomic
white blood cells
diagnostic
Control
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
Collaborators: name: National Research Agency, France
First posted: 2008-11-19
Enrollment: 205
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: DIAGNOSTIC

Brief summary: The G protein-coupled receptors (GPCRs) are a family of proteins expressed at the cell membrane. They are composed of 380 members involved in the important functions of the organism and are privileged therapeutic targets.Their expression is highly modulated depending on the metabolic state of the cells, in particular in pathological situations.our study proposes to determine whether GPCR expression modulation could be used as a biomarker, either prognostic or diagnostic, of treatments.To do so , the investigators will determine the expression profile of the 380 human GPCRs in human blood cell samples in two chronic inflammatory pulmonary diseases : asthma and COPD (chronic obstructive pulmonary disease ) . These have opposed inflammatory infiltrates : asthma is associated with eosinophil and Th2 lymphocyte infiltration whereas COPD shows neutrophils and macrophages within the airways with a Th1 lymphocytic population. The GPCR signature (transcriptomic) will be determined on total white blood cells as well as on isolated mono- and poly-nuclear populations obtained from healthy subjects and patients selected at the asthma or COPD consultation. The expression profiling analysis will reveal sub-groups of GPCRs whose expression is modified in disease. The specificity of the variation of expression of these biomarker sub-populations will be determined, by a study recruiting a hundred patients and controls per disease on this restraint number of genes. The outcomes of the project will lead to establish GPCR "identity cards" for these chronic inflammatory diseases, which might therefore be used as diagnostic or prognostic biomarkers to follow the evolution of a disease or the efficacy of a given treatment. In addition, detailed analysis of the identified GPCRs will lead to propose new therapeutic targets for inflammatory diseases. This study has therefore the objective of validating GPCRs as potential biomarkers for inflammatory diseases.

Detailed description: Multicentre non-randomized

Eligibility criteria: Inclusion Criteria:

* Asthma group
* COPD group
* Control group

Exclusion Criteria:

* Patients with infection or inflammatory diseases

Primary outcomes:
measure: differential expression of GPCRs
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Colmar
country: France
facility: Hospital
city: Marseille
country: France
facility: Pascal Chanez
city: Montpellier
country: France
facility: University Hospital
city: Nantes
country: France
facility: Antoine Magnan
city: Strasbourg
country: France
facility: University Hospital, Strasbourg, France
Study officials:
affiliation: University Hospital, Strasbourg, France
name: Romain Kessler, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Gras D, Martinez-Anton A, Bourdin A, Garulli C, de Senneville L, Vachier I, Vitte J, Chanez P. Human bronchial epithelium orchestrates dendritic cell activation in severe asthma. Eur Respir J. 2017 Mar 8;49(3):1602399. doi: 10.1183/13993003.02399-2016. Print 2017 Mar.